-

Xevant Launches VerX: A Bold Strike Against the Rx Cost Crisis

LEHI, Utah--(BUSINESS WIRE)--Xevant, a leader in real-time pharmacy benefits AI and analytics, today announced the launch of VerX (pronounced “Vair-ex”), a powerful new platform that redefines how pharmacy benefits are optimized, managed, and controlled. VerX is the first platform to crack open the black box of pharmacy benefits by reverse engineering prescription claims to reveal the lowest achievable net cost for every claim, in real time.

Built on over eight years of industry-leading data infrastructure and analytics performance, VerX combines predictive modeling, AI simulation, and automated plan correction in a single, scalable platform. VerX is designed for brokers, health plans, PBMs, and self-funded employers looking to identify and achieve immediate savings opportunities and system-level waste across drug mix, channel, formulary, pricing, and rebate alignment.

“The industry doesn't need more dashboards. It needs action,” said Brandon Newman, CEO of Xevant. “VerX isn't just another reporting tool. It's the backbone of next-generation cost containment and entirely new PBM strategies never conceived before. Most platforms monitor. VerX predicts, simulates, and prescribes actions—backed by proof."

VerX was developed with a clear objective: to give payers the same visibility and firepower that PBMs have long used behind the scenes. The platform ingests more than 2,500 daily data feeds, trained on 99% of the PBM market performance, and delivers live, AI-driven insights across:

  • Reverse Engineering: Uncovers real-time, lowest-net-cost pricing by mapping PBM decision patterns.
  • Plan Design Simulation: Forecasts the cost impact of benefit changes before implementation, including PA edits, step therapy, copay, and channel adjustments, and rebate shifts.
  • Post-Implementation Tracking: Compares actual vs. projected savings to ensure accountability across all stakeholders.
  • Contract Performance Monitoring: Flags discrepancies in PBM pricing, discount, and rebate guarantees in real time.
  • Utilization Optimization: Highlights high-cost drug mix inefficiencies and pinpoints biosimilar, dose, or channel alternatives.
  • Rebate Intelligence: Projects accruals and real net cost—no more guesswork or six-month delays.
  • Disruption Analysis: Quantifies the member impact of any savings strategy to protect employee experience.

Xevant expects that organizations using VerX will achieve average savings of 15–25%, with some reaching up to 31% through optimized drug mix, channel management, and formulary realignment. Critically, these savings can be realized mid-contract, without waiting for annual renewals or switching PBMs.

How to Get Started

Xevant invites benefit leaders, health plans, brokers, and consultants to pilot VerX using their own claims data.

Run your claims through VerX and see the missed opportunities in real time. Talk to a Xevant expert here to get started.

About Xevant

Xevant is a healthcare analytics company revolutionizing how pharmacy benefits are managed. Its real-time, AI-powered platforms enable organizations to reduce waste, optimize contract value, and achieve measurable results across commercial and self-funded markets. Headquartered in Lehi, Utah, Xevant serves payers, PBMs, TPAs, brokers, and Fortune 1000 employers nationwide.

For more information, visit www.xevant.com or contact:

Contacts

Media Contact:
Society22 PR
Rachel Moore
929-367-8993
Xevant@society22pr.com

Xevant


Release Versions

Contacts

Media Contact:
Society22 PR
Rachel Moore
929-367-8993
Xevant@society22pr.com

More News From Xevant

Ivím at Work, Offered by Ivím Health and Xevant, Named Gold Stevie® Award Winner in 2025 American Business Awards®

LEHI, Utah--(BUSINESS WIRE)--Ivím at Work, a joint solution from Ivím Health and Xevant, has been named the winner of the Gold Stevie® Award in the Consumer Products category in the 23rd Annual American Business Awards®. The American Business Awards are the premier business awards program in the U.S., open to public and private, for-profit and nonprofit organizations of all sizes. Nicknamed the Stevies—from the Greek word meaning “crowned”—the awards will be presented at a gala ceremony on Tues...

Xevant Unveils 2025 Drug Price Inflation White Paper: A Data-Driven Look at Rising Pharmaceutical Costs and Future Implications

LEHI, Utah--(BUSINESS WIRE)--Xevant, a leading provider of real-time data analytics for pharmacy benefit management, today announced the release of its 2025 Drug Price Inflation White Paper, providing key insights into the ongoing surge in pharmaceutical prices and what it means for payers, employers, and pharmacy benefit managers (PBMs). As the cost of healthcare continues to escalate, the new year has brought a fresh wave of price hikes across the pharmaceutical landscape. Within the first tw...

Xevant Introduces the All-New Biosimilar Dashboard, A Real-Time Analytics Tool to Accelerate Biosimilar Adoption and Reduce Unnecessary Biologic Drug Spend

LEHI, Utah--(BUSINESS WIRE)--Xevant, a leader in pharmacy benefits automation, today announces the launch of its all-new Biosimilar Dashboard, a real-time analytics tool designed to streamline biosimilar adoption and reduce unnecessary spending on biologic drugs. The Biosimilar Dashboard empowers health plans, employers, pharmacy benefit managers (PBMs), consultants, and benefits advisors by transforming fragmented prescription data into timely, actionable insights. This enhanced visibility ena...
Back to Newsroom